--- title: "Matinas Biopharma effects one-for-fifteen reverse stock split" url: "https://aibio.space/news/matinas-biopharma-effects-one-fifteen-reverse-stock-split/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-09-25" section: "Listings" tickers: "AMEX:MTNB" source: "https://www.sec.gov/Archives/edgar/data/1582554/000149315226044451/form8-k.htm" summary: "The reverse split of Matinas BioPharma Holdings took effect at 12:01 a.m. Eastern Time on September 28, 2026. Every 15 shares of common stock became one sh" --- By the aibio.space news desk. Sources - [Form 8-K, SEC EDGAR](https://www.sec.gov/Archives/edgar/data/1582554/000149315226044451/form8-k.htm) - [Matinas Biopharma Holdings, Inc. 10-K (2026-03-31): business](https://www.sec.gov/Archives/edgar/data/1582554/000149315226014132/form10-k.htm) - [Matinas Biopharma Holdings, Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1582554/000149315226014132/) [MTNB](https://aibio.space/companies/matinas-biopharma/) 2026-09-25 # Matinas Biopharma effects one-for-fifteen reverse stock split Tickers [MTNB](https://aibio.space/companies/matinas-biopharma/) The reverse split of Matinas BioPharma Holdings took effect at 12:01 a.m. Eastern Time on September 28, 2026. Every 15 shares of common stock became one share. ## Key facts - **Company**: Matinas Biopharma Holdings, Inc. (AMEX: MTNB) - **News type**: Listings - **Primary source**: [Form 8-K, SEC EDGAR](https://www.sec.gov/Archives/edgar/data/1582554/000149315226044451/form8-k.htm) *A stone federal courthouse. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.* Matinas BioPharma Holdings, Inc. (NYSE American: [MTNB](https://aibio.space/companies/matinas-biopharma/)) reported in a Form 8-K dated September 25, 2026 that it filed a Certificate of Amendment with the Delaware Secretary of State. The amendment effected a one-for-fifteen reverse stock split of its common stock, $0.0001 par value per share. The split took effect at 12:01 a.m. Eastern Time on September 28, 2026. ## The split Every fifteen shares of common stock issued and outstanding became one share. The company says the split affected all stockholders uniformly and did not change any stockholder's percentage interest, except where a stockholder would have owned a fractional share. No fractional shares were issued. Stockholders who would have received a fractional share receive a proportional cash payment instead. The split did not change the par value of the common stock or the number of authorized shares. Stock options, warrants and convertible preferred stock were adjusted under their terms. The CUSIP number for the common stock changed to 576810 402. The company anticipates that its common stock will begin trading on a split-adjusted basis on the NYSE American when the market opens on September 28, 2026. That is subject to approval by the exchange. ## The approval The company's stockholders voted to approve the Certificate of Amendment at the annual meeting held on June 23, 2025. The board of directors approved and authorized the filing of the Certificate of Amendment on September 16, 2026. The 8-K attaches the certificate as Exhibit 3.1. The filing does not give a reason for the split. ## What the company does Matinas describes itself as a clinical-stage biopharmaceutical company. Its work centers on a lipid nanocrystal platform, a delivery technology it calls the LNC Platform. Its lead product candidate is MAT2203, an oral form of amphotericin B that the company says is intended for life-threatening invasive fungal infections. After the EnACT Phase 2 trial in cryptococcal meningitis, the company says MAT2203 is positioned for a single Phase 3 registration trial, called the ORALTO trial, in support of a New Drug Application for invasive aspergillosis in patients with limited treatment options. The company says it has paused clinical development of MAT2203 and is in an ongoing partnership process to find development or commercialization partners. The company also reduced its workforce by 80% in late October 2024. The annual report says it has paused internal development of its LNC Platform pipeline while it evaluates strategic alternatives for those early-stage oncology and inflammatory programs. ## The company's financial position The annual report for 2025 shows research and development expense of $85,000 for 2025, against $11.4 million for 2024. The net loss was $10.3 million for 2025 and $24.3 million for 2024. Cash used in operations was $7.0 million in 2025 and $15.9 million in 2024. A quarterly report filed in August 2026 reported year-end cash and cash equivalents of $4.0 million for 2025 and $7.3 million for 2024. ## Earlier reverse split The company's annual report describes an earlier reverse split. The company received notice on August 27, 2024 that the NYSE American had halted trading in its shares due to the low trading price. The one-for-fifty split took effect on August 30, 2024, and the shares began trading on a split-adjusted basis when the market opened on September 3, 2024. ## What the split leaves unsolved This is the company's second reverse split in about two years, after the one-for-fifty in August 2024, and trading on the new basis still needs the exchange's approval. The split changes the share count, not the business. The company cut 80% of its staff in October 2024, has paused development of MAT2203, its lead drug, and says it needs a partner or more capital to start the ORALTO trial. Year-end 2025 cash and cash equivalents of $4.0 million compare with $7.0 million of cash used in operations in 2025, and the company has not found a partner. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story MTNB Matinas Biopharma Holdings, Inc. AMEX ยท United States Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/matinas-biopharma-effects-one-fifteen-reverse-stock-split/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Matinas Biopharma effects one-for-fifteen reverse stock split", 2026-09-25, https://aibio.space/news/matinas-biopharma-effects-one-fifteen-reverse-stock-split/